Pharmaceuticals News and Research

RSS

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

IDRI, a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that they will be presenting positive interim Phase I clinical results for their H5N1 Avian Influenza VLP vaccine candidate "H5N1 vaccine" at the World Vaccine Congress.

9 Apr 2013

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has recently signed an exclusive license agreement with University of California at Los Angeles to develop and market anti-PSA IgE technology for the treatment of cancer.

9 Apr 2013

GSK, A*STAR's ICES to develop new evidence based formulations for emerging markets

GlaxoSmithKline and A*STAR's Institute of Chemical and Engineering Sciences have signed a five-year strategic agreement to develop new evidence based formulations specifically for emerging markets.

9 Apr 2013

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.

9 Apr 2013

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Wolfe Laboratories today announced the presentation of an abstract related to its research efforts surrounding antibody-drug conjugates at the 245th National Meeting of the American Chemical Society, held April 7-11 in New Orleans.

9 Apr 2013

New Japan-driven initiative to accelerate research, development innovation for neglected diseases

The Drugs for Neglected Diseases initiative, based in Geneva, Switzerland, and DNDi Japan, based in Tokyo, welcome the launch of the Global Health Innovative Technology Fund, an initiative supported by the Japanese government, several Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation.

9 Apr 2013

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

The American Association for Cancer Research has chosen Prof. Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research.

9 Apr 2013

World Heart Federation publishes position statement on rheumatic fever, rheumatic heart disease

The World Heart Federation has published a new position statement outlining the five key strategic targets required to meet its strategic goal for rheumatic heart disease - a 25% reduction in premature deaths from rheumatic fever and RHD among individuals aged <25 years by the year 2025.

9 Apr 2013

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

ARIAD Pharmaceuticals, Inc. today announced the presentation of preclinical data on ponatinib (Iclusig) , at the American Association for Cancer Research Annual Meeting 2013, in Washington.

9 Apr 2013

Clinical data of two Transgene products to be presented at EASL Conference

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).

9 Apr 2013

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration has approved the company's New Drug Application for PROLENSA (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

9 Apr 2013

New national study examines marijuana use and prescription drug misuse

Individuals who use marijuana recreationally are more likely to misuse other drugs, including pain-controlling, but potentially addictive narcotics, sedatives and other prescription medications, than individuals who do not use marijuana, according to a new national study issued today by Quest Diagnostics, the world's leading provider of diagnostic information services.

From Quest Diagnostics 9 Apr 2013

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.

9 Apr 2013

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that the Instituto de Salud Publica of Chile has approved the Company's protocol for its Phase 2 clinical study of TI-001, intranasal oxytocin, for the treatment of chronic migraine.

9 Apr 2013

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Anacor Pharmaceuticals today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis.

9 Apr 2013

Obama's budget expected to call for Medicare cuts

n advance of the release of President Barack Obama's fiscal blueprint on Wednesday, an adviser warned friends and foes that the plan includes things neither will like. The budget plan is expected to kick off new discussions about trimming entitlements and revamping the nation's safety net.

9 Apr 2013

GE Healthcare releases next-generation sequencing assay for use in clinical trials

GE Healthcare announced today that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials.

8 Apr 2013

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.

8 Apr 2013

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

NewLink Genetics Corporation, a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American Association for Cancer Research 2013 annual meeting.

8 Apr 2013

Lipocine announces favorable Phase I study results for LPCN 1111

Lipocine Inc., a biopharmaceutical company focused on developing innovative oral hormone therapies for men's and women's health, today announced favorable Phase I results for LPCN 1111.

8 Apr 2013

Pharmaceuticals News and Research

Medicago, IDRI to present Phase I clinical results of H5N1 vaccine at World Vaccine Congress

Quest PharmaTech to develop, market anti-PSA IgE technology for cancer treatment

GSK, A*STAR's ICES to develop new evidence based formulations for emerging markets

Exosome profiling of mRNAs and miRNAs in serum samples presented at AACR meeting

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

New Japan-driven initiative to accelerate research, development innovation for neglected diseases

Hebrew University professor wins 2013 Award for Outstanding Achievement in Chemistry in Cancer Research

World Heart Federation publishes position statement on rheumatic fever, rheumatic heart disease

ARIAD Pharmaceuticals presents preclinical data on ponatinib at AACR Annual Meeting 2013

Clinical data of two Transgene products to be presented at EASL Conference

FDA approves PROLENSA for treatment of inflammation, pain after cataract surgery

New national study examines marijuana use and prescription drug misuse

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

ISP of Chile approves Trigemina's protocol for Phase 2 clinical study of TI-001

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Obama's budget expected to call for Medicare cuts

GE Healthcare releases next-generation sequencing assay for use in clinical trials

Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

Preclinical data for potent IDO pathway inhibitor presented at AACR 2013 annual meeting

Lipocine announces favorable Phase I study results for LPCN 1111

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence